Heat Biologics: Investors Would Be Wise To Hold Off Until 2H 2021 Clinical Trial Interim Results (NASDAQ:HTBX) 1970-01-01T00:00:00-05:00January 1st, 1970| share this article! Heat Biologics, Inc. is a clinical-stage biopharmaceutical stage company focused on developing immune therapies and vaccines. Read More share this article! Related Posts ESR(01821.HK)回购200.06万股 涉资约1979.17万港元 February 14th, 2024 阿里巴巴将股份回购计划增加250亿美元 February 13th, 2024 Facing Failure, Vote On EU Corporate Sustainability Due Diligence Law Delayed February 9th, 2024 Lawmakers And Regulators Tackle AI’s Antitrust Risks February 9th, 2024
